Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab.
作者信息
Ruiz-Moreno J M, Montero J A, Gomez-Ulla F
出版信息
Br J Ophthalmol. 2009 Dec;93(12):1693-4. doi: 10.1136/bjo.2008.147611.
PMID:19939802
Abstract
摘要
相似文献
1
Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab.
Br J Ophthalmol. 2009 Dec;93(12):1693-4. doi: 10.1136/bjo.2008.147611.
2
Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.玻璃体内注射贝伐单抗治疗高度近视眼中黄斑中心凹下脉络膜新生血管：1年随访结果
Br J Ophthalmol. 2009 Apr;93(4):448-51. doi: 10.1136/bjo.2008.145391. Epub 2008 Dec 17.
3
Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.两种方法治疗近视性脉络膜新生血管的两年比较：光动力疗法与玻璃体内注射贝伐单抗。
Br J Ophthalmol. 2010 Jul;94(7):864-70. doi: 10.1136/bjo.2009.166025. Epub 2009 Dec 3.
4
Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.玻璃体腔内注射贝伐单抗或光动力疗法后近视性脉络膜新生血管的视力预后及消退模式比较
Am J Ophthalmol. 2009 Sep;148(3):396-408. doi: 10.1016/j.ajo.2009.03.026. Epub 2009 May 9.
5
Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.玻璃体内贝伐单抗治疗高度近视眼中的中心性脉络膜新生血管：短期结果。
Eye (Lond). 2009 Feb;23(2):334-8. doi: 10.1038/sj.eye.6703052. Epub 2007 Dec 7.
6
Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.玻璃体内注射贝伐单抗治疗近视性脉络膜新生血管的 12 个月疗效。
Retina. 2010 Nov-Dec;30(10):1609-15. doi: 10.1097/IAE.0b013e3181e22659.
7
Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results.玻璃体腔雷珠单抗治疗病理性近视继发脉络膜新生血管：12 个月的结果。
Eye (Lond). 2009 Jun;23(6):1275-80; quiz 1281. doi: 10.1038/eye.2009.88. Epub 2009 May 29.
8
Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗近视性脉络膜新生血管：一项前瞻性试点研究的1年结果
Br J Ophthalmol. 2009 Feb;93(2):150-4. doi: 10.1136/bjo.2008.145797. Epub 2008 Sep 18.
9
Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.玻璃体腔注射贝伐单抗治疗病理性近视性脉络膜新生血管
Retina. 2006 Oct;26(8):960-3. doi: 10.1097/01.iae.0000240121.28034.c3.
10
Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration.玻璃体内注射贝伐单抗治疗与年龄相关性黄斑变性无关的原因引起的脉络膜新生血管。
Eye (Lond). 2010 Feb;24(2):203-13. doi: 10.1038/eye.2009.201. Epub 2009 Aug 7.
引用本文的文献
1
[Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].[德国眼科学会、德国视网膜学会和德国眼科医生专业协会关于近视性脉络膜新生血管治疗的声明。发布时间：2014年3月]
Ophthalmologe. 2014 Mar;111(3):229-34. doi: 10.1007/s00347-014-3035-y.
Zotero 插件